Regenxbio Inc. (RGNX) PT Lowered to $127.50 at Chardan Capital Markets; Sees Low Bar in Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Regenxbio Inc. (RGNX) PT Lowered to $127.50 at Chardan Capital Markets; Sees Low Bar in Wet AMD

Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

August 8, 2018 7:44 AM EDT

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of $0.30, $0.93 worse than the analyst estimate of $1.23. Revenue for the quarter came in at $40.03 million versus the consensus estimate of $100 million.

"We are very encouraged by the positive interim data for RGX-314 and the potential of NAV gene therapy as a one-time treatment for wet AMD,... More